{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:54:45Z","timestamp":1791507285169,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["Creating training hubs for advanced medical personnel (Supporting the fostering of doctors with advanced clinical and research capabilities)"],"award-info":[{"award-number":["Creating training hubs for advanced medical personnel (Supporting the fostering of doctors with advanced clinical and research capabilities)"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007312","name":"National Center for Geriatrics and Gerontology","doi-asserted-by":"publisher","award":["the Research Funding for Longevity Sciences (Nos. 19-20, 22-26)"],"award-info":[{"award-number":["the Research Funding for Longevity Sciences (Nos. 19-20, 22-26)"]}],"id":[{"id":"10.13039\/501100007312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20lk0201124 and JP19lk0201101"],"award-info":[{"award-number":["JP20lk0201124 and JP19lk0201101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01198-3","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:02:53Z","timestamp":1764583373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Keita","family":"Hiraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Tamakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Arahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshino","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Washimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"1198_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40035-022-00286-1","volume":"11","author":"P Mahlknecht","year":"2022","unstructured":"Mahlknecht, P., Marini, K., Werkmann, M., Poewe, W. & Seppi, K. Prodromal Parkinson\u2019s disease: hype or hope for disease-modification trials?. Transl. Neurodegener. 11, 11 (2022).","journal-title":"Transl. Neurodegener."},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet 386, 896\u2013912 (2015).","journal-title":"Lancet"},{"key":"1198_CR3","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1007\/s00415-020-09714-6","volume":"267","author":"M Hattori","year":"2020","unstructured":"Hattori, M. et al. Subjects at risk of Parkinson\u2019s disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study. J. Neurol. 267, 1516\u20131526 (2020).","journal-title":"J. Neurol."},{"key":"1198_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41531-023-00507-y","volume":"9","author":"M Hattori","year":"2023","unstructured":"Hattori, M. et al. Clinico-imaging features of subjects at risk of Lewy body disease in NaT-PROBE baseline analysis. NPJ Parkinsons Dis. 9, 67 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1198_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41531-024-00745-8","volume":"10","author":"K Hiraga","year":"2024","unstructured":"Hiraga, K. et al. Plasma biomarkers of neurodegeneration in patients and high risk subjects with Lewy body disease. NPJ Parkinsons Dis. 10, 135 (2024).","journal-title":"NPJ Parkinsons Dis"},{"key":"1198_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","volume":"68","author":"M Murata","year":"2007","unstructured":"Murata, M., Hasegawa, K. & Kanazawa, I. Zonisamide on PD Study Group. Zonisamide improves motor function inParkinson disease: a randomized, double-blind study. Neurology 68, 45\u201350 (2007).","journal-title":"Neurology"},{"key":"1198_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mds.26286","volume":"30","author":"M Murata","year":"2015","unstructured":"Murata, M. et al. Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study: Zonisamide Improves Wearing-Off. Mov. Disord. 30, 1343\u20131350 (2015).","journal-title":"Mov. Disord."},{"key":"1198_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.parkreldis.2019.12.005","volume":"76","author":"M Murata","year":"2020","unstructured":"Murata, M. et al. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: a phase 3 randomized clinical trial. Parkinsonism Relat. Disord. 76, 91\u201397 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1198_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.574652","volume":"14","author":"C Li","year":"2020","unstructured":"Li, C. et al. Zonisamide for the treatment of Parkinson disease: a current update. Front. Neurosci. 14, 574652 (2020).","journal-title":"Front. Neurosci."},{"key":"1198_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2018.05.013","volume":"391","author":"K Ikeda","year":"2018","unstructured":"Ikeda, K. et al. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: a retrospective, observational cohort study. J. Neurol. Sci. 391, 5\u20139 (2018).","journal-title":"J. Neurol. Sci."},{"key":"1198_CR11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamaneurol.2017.0985","volume":"74","author":"D Jennings","year":"2017","unstructured":"Jennings, D. et al. Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol. 74, 933\u2013940 (2017).","journal-title":"JAMA Neurol."},{"key":"1198_CR12","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","volume":"90","author":"M Murata","year":"2018","unstructured":"Murata, M. et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology 90, e664\u2013e672 (2018).","journal-title":"Neurology"},{"key":"1198_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ana.27166","volume":"97","author":"MH Flores-Torres","year":"2024","unstructured":"Flores-Torres, M. H. Identifying individuals in the prodromal phase of Parkinson's disease: a prospective cohort study. Ann. Neurol. 97, 720\u2013729 (2024).","journal-title":"Ann. Neurol."},{"key":"1198_CR14","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/mds.24985","volume":"27","author":"D Berg","year":"2012","unstructured":"Berg, D., Marek, K., Ross, G. W. & Poewe, W. Defining at-risk populations for Parkinson\u2019s disease: lessons from ongoing studies. Mov. Disord. 27, 656\u2013665 (2012).","journal-title":"Mov. Disord."},{"key":"1198_CR15","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower, J. H. et al. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain 136, 2419\u20132431 (2013).","journal-title":"Brain"},{"key":"1198_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/jnnp-2021-328742","volume":"93","author":"T Naito","year":"2022","unstructured":"Naito, T. et al. Comparative whole transcriptome analysis of Parkinson\u2019s disease focusing on the efficacy of zonisamide. J. Neurol. Neurosurg. Psychiatry 93, 509\u2013512 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1198_CR17","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00259-018-3976-5","volume":"45","author":"H Matsuda","year":"2018","unstructured":"Matsuda, H. et al. Japanese multicenter database of healthy controls for [123I]FP-CIT SPECT. Eur. J. Nucl. Med. Mol. Imaging 45, 1405\u20131416 (2018).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1198_CR18","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.2967\/jnumed.114.142794","volume":"56","author":"K Nakajima","year":"2015","unstructured":"Nakajima, K. & Nakata, T. Cardiac 123I-MIBG imaging for clinical decision making: 22-year experience in Japan. J. Nucl. Med. 56, 11S\u201319S (2015).","journal-title":"J. Nucl. Med."},{"key":"1198_CR19","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinsonas disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"1198_CR20","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/mds.29582","volume":"38","author":"T Totsune","year":"2023","unstructured":"Totsune, T. et al. Nuclear imaging data-driven classification of Parkinson\u2019s disease. Mov. Disord. 38, 2053\u20132063 (2023).","journal-title":"Mov. Disord."},{"key":"1198_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jnc.13116","volume":"134","author":"H Sano","year":"2015","unstructured":"Sano, H., Murata, M. & Nambu, A. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson\u2019s disease. J. Neurochem. 134, 371\u2013381 (2015).","journal-title":"J. Neurochem."},{"key":"1198_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuint.2019.01.011","volume":"124","author":"H Sano","year":"2019","unstructured":"Sano, H. & Nambu, A. The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson\u2019s disease model mice. Neurochem. Int. 124, 171\u2013180 (2019).","journal-title":"Neurochem. Int."},{"key":"1198_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11011-010-9212-z","volume":"25","author":"H Yokoyama","year":"2010","unstructured":"Yokoyama, H. et al. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice. Metab. Brain Dis. 25, 305\u2013313 (2010).","journal-title":"Metab. Brain Dis."},{"key":"1198_CR24","doi-asserted-by":"publisher","first-page":"e89076","DOI":"10.1371\/journal.pone.0089076","volume":"9","author":"S Arawaka","year":"2014","unstructured":"Arawaka, S. et al. Zonisamide attenuates \u03b1-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson\u2019s disease. PLoS ONE 9, e89076 (2014).","journal-title":"PLoS ONE"},{"key":"1198_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ana.21885","volume":"67","author":"M Asanuma","year":"2010","unstructured":"Asanuma, M. et al. Neuroprotective effects of zonisamide target astrocyte. Ann. Neurol. 67, 239\u2013249 (2010).","journal-title":"Ann. Neurol."},{"key":"1198_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejphar.2012.05.012","volume":"689","author":"ME Choudhury","year":"2012","unstructured":"Choudhury, M. E. et al. Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors. Eur. J. Pharmacol. 689, 72\u201380 (2012).","journal-title":"Eur. J. Pharmacol."},{"key":"1198_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neulet.2010.06.058","volume":"481","author":"S Kawajiri","year":"2010","unstructured":"Kawajiri, S., Machida, Y., Saiki, S., Sato, S. & Hattori, N. Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci. Lett. 481, 88\u201391 (2010).","journal-title":"Neurosci. Lett."},{"key":"1198_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejphar.2014.09.023","volume":"746","author":"S Tsujii","year":"2015","unstructured":"Tsujii, S., Ishisaka, M., Shimazawa, M., Hashizume, T. & Hara, H. Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo. Eur. J. Pharmacol. 746, 301\u2013307 (2015).","journal-title":"Eur. J. Pharmacol."},{"key":"1198_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s12031-011-9638-8","volume":"46","author":"T Omura","year":"2012","unstructured":"Omura, T. et al. HRD1 levels increased by zonisamide prevented cell death and caspase-3 activation caused by endoplasmic reticulum stress in SH-SY5Y cells. J. Mol. Neurosci. 46, 527\u2013535 (2012).","journal-title":"J. Mol. Neurosci."},{"key":"1198_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.expneurol.2009.11.002","volume":"221","author":"C Costa","year":"2010","unstructured":"Costa, C. et al. Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction. Exp. Neurol. 221, 217\u2013224 (2010).","journal-title":"Exp. Neurol."},{"key":"1198_CR31","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1007\/s11064-013-1181-2","volume":"38","author":"S Condello","year":"2013","unstructured":"Condello, S. et al. Protective effects of zonisamide against rotenone-induced neurotoxicity. Neurochem. Res. 38, 2631\u20132639 (2013).","journal-title":"Neurochem. Res."},{"key":"1198_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1447-0594.2008.00463.x","volume":"8","author":"A Hagiwara","year":"2008","unstructured":"Hagiwara, A., Ito, N., Sawai, K. & Kazuma, K. Validity and reliability of the Physical Activity Scale for the Elderly (PASE) in Japanese elderly people. Geriatr. Gerontol. Int. 8, 143\u2013151 (2008).","journal-title":"Geriatr. Gerontol. Int."},{"key":"1198_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.clineuro.2014.07.007","volume":"124","author":"M Matsushima","year":"2014","unstructured":"Matsushima, M., Yabe, I., Hirotani, M., Kano, T. & Sasaki, H. Reliability of the Japanese version of the scales for outcomes in Parkinson\u2019s disease-autonomic questionnaire. Clin. Neurol. Neurosurg. 124, 182\u2013184 (2014).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1198_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.anl.2010.05.013","volume":"38","author":"H Takebayashi","year":"2011","unstructured":"Takebayashi, H. et al. Clinical availability of a self-administered odor questionnaire for patients with olfactory disorders. Auris Nasus Larynx 38, 65\u201372 (2011).","journal-title":"Auris Nasus Larynx"},{"key":"1198_CR35","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.sleep.2009.05.007","volume":"10","author":"T Miyamoto","year":"2009","unstructured":"Miyamoto, T. et al. The REM sleep behavior disorder screening questionnaire: validation study of a Japanese version. Sleep. Med. 10, 1151\u20131154 (2009).","journal-title":"Sleep. Med."},{"key":"1198_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0165-1781(02)00106-3","volume":"110","author":"M Kojima","year":"2002","unstructured":"Kojima, M. et al. Cross-cultural validation of the Beck Depression Inventory-II in Japan. Psychiatry Res. 110, 291\u2013299 (2002).","journal-title":"Psychiatry Res."},{"key":"1198_CR37","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.sleep.2008.04.015","volume":"10","author":"M Takegami","year":"2009","unstructured":"Takegami, M. et al. Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on item response theory. Sleep. Med. 10, 556\u2013565 (2009).","journal-title":"Sleep. Med."},{"key":"1198_CR38","unstructured":"Kohmoto, J., et al. Validation of the Japanese version of the Parkinson\u2019s disease questionnaire. Rinsho Shinkeigaku 43, 71\u201376 (2003)."},{"key":"1198_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jns.2013.05.013","volume":"331","author":"K Tanaka","year":"2013","unstructured":"Tanaka, K., Wada-Isoe, K., Nakashita, S., Yamamoto, M. & Nakashima, K. Impulsive compulsive behaviors in Japanese Parkinson\u2019s disease patients and utility of the Japanese version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u2019s disease. J. Neurol. Sci. 331, 76\u201380 (2013).","journal-title":"J. Neurol. Sci."},{"key":"1198_CR40","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"1198_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01198-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01198-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01198-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:02:57Z","timestamp":1764583377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01198-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01198-3","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K. receives research grants from Sumitomo Pharma and Nihon Medi-physics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"322"}}